- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03835377
Iron-Biofortified Beans Intervention in Mexico
A Randomized Feeding Trial of Iron-Biofortified Beans in School Children in Mexico
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Iron deficiency is the most common single nutrient deficiency worldwide, with the highest burden in children and women of reproductive age. Global estimates of anemia prevalence in school-aged children range between 25% and 46%, and iron deficiency accounts for a majority of anemia cases. In Mexico, the national nutrition and health survey (2006) reported a prevalence of anemia of 16.6% and iron deficiency of 17.6% (serum ferritin <12.0 µg/L), posing a considerable health risk for children.
Interventions, including micronutrient supplementation and food fortification, have improved iron status and reduced the prevalence of anemia in some settings. However, iron deficiency remains an urgent public health problem and threat to child health and development. Young children are particularly at high risk due to rapid growth, inadequate dietary intake, and high risk of infection in resource-limited settings. Iron deficiency has been associated with impaired cognitive function in children, and long-term impairments in physical work capacity into adulthood.
One novel approach to reducing micronutrient malnutrition is to enhance the nutrient quality of the diet through biofortification of staple crops that are already locally accepted and consumed. Biofortification has consequently been recognized by the Copenhagen Consensus of 2008 as one of the top five solutions to current global health and nutrition challenges. The success and challenges of biofortification have been documented previously. We recently reviewed the published evidence from the three randomized efficacy trials of different iron-biofortified crops that demonstrated varied benefits in populations, including rice in adult Filipino women, pearl millet in school-aged children in India, and beans in women of reproductive age in Rwanda. Findings demonstrated improvements in serum ferritin concentrations and total body iron concentrations, with additional potential to benefit in individuals who were iron deficient at baseline. Given this limited evidence and with no studies from Latin America, more studies with diverse populations and locally relevant crops are warranted before implementation of a potentially important public health intervention.
In order to target at-risk populations in Latin America, the Centro Internacional de Agricultura Tropical (CIAT) in Colombia bred and biofortified a common black bean variety (Phaseolus vulgaris L), the standard black bean currently consumed widely in Central America and Mexico. In Mexico, beans have been ranked highly among the most consumed foods by school-aged children nationwide, according to Encuesta Nacional de Salud y Nutrición, a nationally representative nutrition survey in 2006. Biofortification has nearly doubled the iron concentration (~100 versus ~50 mg/kg) of the standard bean variety. We hypothesized that daily consumption of iron-biofortified beans (Fe-Beans) would improve hemoglobin, serum ferritin, and total body iron in 6 months, compared to control beans (Control-Beans). In order to examine this hypothesis, we conducted the first randomized efficacy trial of iron-biofortified beans and iron status in primary school-aged children in a low-income setting in Mexico. Special consideration was applied to assess indicators of iron status with and without anemia and measured inflammatory markers, which can mask iron deficiency, particularly in similar settings where the prevalence of infection is high.
The objective of this cluster-randomized efficacy feeding trial was to determine the effects of consuming iron-biofortified beans (Fe-Beans) on iron status in children, compared to control beans (Control-Beans).
The long-term goal of this study is to determine if iron bio-fortification of beans is an efficacious and potentially effective strategy to improve iron status of at-risk populations in resource-limited settings.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Morelos
-
Cuernavaca, Morelos, Mexico
- Instituto Nacional de Salud Pública (INSP)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Boarding schools for children (5-12 y)
- Located in a rural area approximately 60 kilometers east of the city of Oaxaca
- A high prevalence of anemia (>=15.0%) on the baseline survey
- Adequate infrastructure to sustain a 6-month feeding trial. Exclusion criteria were a prevalence of anemia of less than 15% on the baseline survey, and inadequate infrastructure to sustain a 6-month feeding trial
Exclusion Criteria:
- A prevalence of anemia <15.0% on the baseline survey
- Inadequate infrastructure to sustain a 6-month feeding trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Iron-biofortified beans
Iron-biofortified beans (Phaseolus vulgaris L MIB465)
|
Iron-biofortified beans (Phaseolus vulgaris L MIB465)
Other Names:
|
ACTIVE_COMPARATOR: Control beans
Control beans (Phaseolus vulgaris L Jamapa variety)
|
Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hemoglobin
Time Frame: 6 months
|
Hemoglobin (Hb)
|
6 months
|
Change in serum ferritin
Time Frame: 6 months
|
Serum ferritin (SF)
|
6 months
|
Change in sTfR
Time Frame: 6 months
|
Soluble transferrin receptor (sTfR)
|
6 months
|
Anemia
Time Frame: 6 months
|
Hb <115 g/L for <12 y; <120 g/L for >=12 y
|
6 months
|
Iron deficiency (SF)
Time Frame: 6 months
|
Serum ferritin <15.0 µg/L
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in TBI
Time Frame: 6 months
|
Total body iron (TBI)
|
6 months
|
Iron deficiency (TBI)
Time Frame: 6 months
|
TBI <0.0 mg/kg
|
6 months
|
Iron deficiency (sTfr)
Time Frame: 6 months
|
sTfr >8.3 μg/mL
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Salvador Villalpando, MD PhD, Instituto Nacional de Salud Pública (INSP)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CI-441
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron-deficiency
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
-
Swiss Federal Institute of TechnologyUniversity of MalawiCompletedIron-deficiency | Iron Deficiency AnemiaMalawi, Switzerland
-
Johann Wolfgang Goethe University HospitalLudwig-Maximilians - University of MunichCompletedNon-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IXIron-deficiency | Anemia | Iron Deficiency AnemiaGermany
-
Kansas State UniversityUnited States Department of Agriculture Foreign Agricultural Service; American...CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Bioavailability | Anemia, Iron Deficiency | Absorption; Iron | Serum IronUnited States
Clinical Trials on Iron-biofortified beans
-
Swiss Federal Institute of TechnologyHarvestPlusCompleted
-
Instituto de Investigacion Nutricional, PeruUniversity of East Anglia; Quadram Institute BioscienceCompleted
-
Cornell UniversityPenn State University; University of the PhilippinesCompleted
-
Swiss Federal Institute of TechnologyUniversité d'Abomey-CalaviCompletedIron Deficiency | BiofortificationBenin
-
Dr. Peter ZahradkaManitoba Pulse GrowersCompleted
-
Cornell UniversityArogyavaram Medical Centre; SNDT Women's UniversityActive, not recruitingIron Deficiency | Vitamin A Deficiency | Zinc DeficiencyIndia
-
M.D. Anderson Cancer CenterActive, not recruitingColorectal Cancer PreventionUnited States
-
University of Colorado, Colorado SpringsIowa State UniversityCompletedType 2 Diabetes
-
Arizona State UniversityUnited States Dry Bean CouncilCompletedType 2 Diabetes Mellitus | Blood GlucoseUnited States
-
Queen Mary University of LondonUniversity of Southampton; Ministry of Health and Child Welfare, Zimbabwe; CI...Active, not recruiting